Cambridge Heart Holds Annual Stockholders Meeting; Major Accomplishments and Milestones of 2000/2001 Reported.

Business/Technology Editors and Health/Medical Writers

BEDFORD, Mass.--(BW HealthWire)--May 31, 2001

Cambridge Heart, Inc. (NASDAQ:CAMH) today held its Annual Meeting of Stockholders in Boston, Massachusetts, where President and CEO David A. Chazanovitz presented Shareholders with an overview of the Company's impressive list of 2000 and 2001 achievements. Shareholders also cast votes in favor of all matters recommended for approval by the Board of Directors detailed in the Company's 2001 Proxy Statement.

In outlining Cambridge Heart's progress and major accomplishments Mr. Chazanovitz specifically highlighted achievements related to reimbursement for the Company's Microvolt T-Wave Alternans Test, the introduction of the new Heartwave system, key distribution partnerships with major medical products companies, and publication of important new clinical data enhancing the creditability of the Alternans test.

Mr. Chazanovitz noted that during the past year:

- The American Medical Association granted a Category I CPT Code for the
Microvolt T-Wave Alternans Test that will be available for use in January 2002.


- Medicare's Cardiology Working Group developed a model coverage policy for the
payment of physician services that is available as guidance on coverage and
payment to all 42 local Medicare payers.

- Medicare announced the availability of reimbursement for hospital outpatients
under a new Prospective Payment Plan utilizing APC Code 0096.

- During the year the Company received FDA clearance to market its Heartwave
system. Initial shipments of the product began in September 2000.

- The Company entered into a strategic marketing alliance with Spacelabs
Medical, Inc. for the distribution of its Microvolt T-Wave Alternans technology
as a feature on their Quest stress test system. Additionally, in March, 2001
the Company signed an agreement with Agilent Technologies, Inc. making them the
exclusive U.S. distributor of its CH 2000 stress test system,

- Three peer reviewed journal articles appeared in major medical publications
demonstrating the effectiveness of Microvolt T-Wave Alternans in assessing
patients at risk in three important cardiac populations. Two of these articles
were published in the Journal of the American College of Cardiology and one in
the prestigious British journal The Lancet.

Mr. Chazanovitz also took the occasion of the Annual Meeting to acknowledge and thank Jeffrey M. Arnold for his many years of service to Cambridge Heart. Mr. Arnold will discontinue his day-to-day duties at the Company, although he will remain as Chairman of the Board of Directors in a non executive capacity. "I know I speak for all Shareholders, directors, advisors and employees of the Company when I express my admiration and sincere gratitude for Jeff's dedication to the development and success of Cambridge Heart and its Microvolt T-Wave Alternans technology" said Mr. Chazanovitz. "We would not be poised for the future success we anticipate without the benefit of his vision and commitment. We all wish him all the best for the future an will continue to rely on his sage advice."

About the Cambridge Heart Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected during a typical treadmill or bicycle exercise stress test by proprietary sensors placed on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack. The Company, founded in 1992, is based in Bedford, Massachusetts and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements made in this news release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements including uncertainties concerning market acceptance, reimbursement and other factors that are included in Cambridge Heart's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.